Aidan King

Developing therapies to improve quality of life in Alzheimers disease

Ermium Therapeutics is a discovery stage Biotechnology company developping innovative therapies for auto-immune diseases

Development of transformative therapies for the treatment of worsening and acute decompensated heart failure

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

Chrono Therapeutics is focused on improving clinical outcomes for patients battling addictions and living with neurological disorders via our proprietary Digital Patch platform, pioneering a new era of transdermal drug delivery designed to meet each patient's individual needs. By integrating timed drug delivery with personalized, mobile-phone-based digital support and unique data analytics to maximize compliance, we help patients manage hard to treat conditions and optimize clinical outcomes. We have multiple programs in active development that address significant market opportunities with unmet (or poorly) met needs. Each of our programs leverages medications that readily cross the skin. In addition to the programs currently in development for smoking cessation, Parkinson's Disease dyskinesia and prescription opioid dependence, our discovery pipeline is robust, with a number of CNS indications under evaluation that would benefit from a therapeutic combined with behavioral and compliance support.

Palyon Medical Corporation has developed a novel, state-of-the-art programmable Implantable Drug Delivery System (IDDS). The Palyon IDDS is an infusion pump to deliver medication for the treatment of chronic pain, spasticity, diseases of the central nervous system and chronic metabolic diseases. Palyon’s mission is to provide the market with the broadest range of implantable infusion devices that offer an unparalleled feature set to address a broad range of unmet medical needs.

Developing therapies to improve quality of life in Alzheimers disease

Ermium Therapeutics is a discovery stage Biotechnology company developping innovative therapies for auto-immune diseases

Development of transformative therapies for the treatment of worsening and acute decompensated heart failure

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.